Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Other Non-Current Liabilities: 2013-2019

Historic Other Non-Current Liabilities for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $6.1 million.

  • Soleno Therapeutics' Other Non-Current Liabilities rose 6.97% to $6.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $6.1 million, marking a year-over-year increase of 6.97%. This contributed to the annual value of $5.6 million for FY2018, which is 11.16% up from last year.
  • Latest data reveals that Soleno Therapeutics reported Other Non-Current Liabilities of $6.1 million as of Q3 2019, which was up 0.46% from $6.0 million recorded in Q2 2019.
  • In the past 5 years, Soleno Therapeutics' Other Non-Current Liabilities ranged from a high of $20.3 million in Q1 2015 and a low of $61,739 during Q4 2016.
  • Its 3-year average for Other Non-Current Liabilities is $3.6 million, with a median of $5.1 million in 2017.
  • Per our database at Business Quant, Soleno Therapeutics' Other Non-Current Liabilities tumbled by 97.25% in 2016 and then skyrocketed by 8,131.43% in 2017.
  • Quarterly analysis of 5 years shows Soleno Therapeutics' Other Non-Current Liabilities stood at $109,404 in 2015, then plummeted by 43.57% to $61,739 in 2016, then skyrocketed by 8,131.43% to $5.1 million in 2017, then rose by 11.16% to $5.6 million in 2018, then climbed by 6.97% to $6.1 million in 2019.
  • Its Other Non-Current Liabilities was $6.1 million in Q3 2019, compared to $6.0 million in Q2 2019 and $5.9 million in Q1 2019.